PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2

Istituto di Cardiologia, Universita di Padova, Italy.

BACKGROUND. The effect of alteplase versus heparin in pulmonary embolism has not been studied extensively with serial pulmonary angiograms. OBJECTIVES. The aim of this randomized, open trial was to evaluate the efficacy and safety of alteplase followed by heparin, versus heparin alone, in 36 patients with angiographically documented pulmonary embolism. METHODS. Twenty patients were allocated randomly to a 2-h infusion of alteplase (10 mg bolus, then 90 mg over 2 h) followed by heparin; the other 16 patients were given intravenous heparin at a continuous infusion rate of 1,750 IU/h. RESULTS. The vascular obstruction, assessed by the Miller index at pulmonary angiography, decreased significantly in alteplase-treated patients (p less than 0.01) from a baseline of 28.3 +/- 2.9 to a value of 24.8 +/- 5.2 2 h after the start of infusion; in the heparin group there was no change (from 25.3 +/- 5.3 to 25.2 +/- 5.4). Mean pulmonary artery pressure decreased significantly from a baseline of 30.2 +/- 7.8 mm Hg to 21.4 +/- 6.7 in the alteplase group and increased in the heparin group (from 22.3 +/- 10.5 to 24.8 +/- 11.2 mm Hg). For a subset of patients, lung scans were performed at baseline and on days 7 and 30. There were no differences between the two groups in the follow-up lung scans, but there were significant decreases from the baseline values. Bleeding occurred in 14 of 20 alteplase-treated patients and in 6 of 16 in the heparin group (p = NS). There were three major bleeding episodes in the alteplase group and two in the heparin group. Two patients died after fibrinolysis (one of acute renal failure after cardiac tamponade and one of cardiac arrest after cerebral hemorrhage) and one patient in the heparin group died of recurrent pulmonary embolism. CONCLUSIONS. Alteplase resulted in a greater and faster improvement of the angiographic and hemodynamic variables compared with heparin. However, the high frequency of bleeding observed with alteplase in this trial suggests that patients should be carefully selected before thrombolytic therapy is given.

This article has been cited by other articles:

				Authors/Task Force Members, A. Torbicki, A. Perrier, S. Konstantinides, G. Agnelli, N. Galie, P. Pruszczyk, F. Bengel, A. J.B. Brady, D. Ferreira, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur. Heart J., September 2, 2008; 29(18): 2276 - 2315. [Full Text] [PDF]

				C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 454S - 545S. [Abstract] [Full Text] [PDF]

				D. J. Perlroth, G. D. Sanders, and M. K. Gould Effectiveness and Cost-effectiveness of Thrombolysis in Submassive Pulmonary Embolism Arch Intern Med, January 8, 2007; 167(1): 74 - 80. [Abstract] [Full Text] [PDF]

				Thromboembolism after pneumonectomy for malignancy: An independent marker of poor outcome. J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 711 - 718.

				P. Prandoni How I treat venous thromboembolism in patients with cancer Blood, December 15, 2005; 106(13): 4027 - 4033. [Abstract] [Full Text] [PDF]

				T. Capstick and M. T. Henry Efficacy of thrombolytic agents in the treatment of pulmonary embolism Eur. Respir. J., November 1, 2005; 26(5): 864 - 874. [Abstract] [Full Text] [PDF]

				T Harris and S Meek When should we thrombolyse patients with pulmonary embolism? A systematic review of the literature Emerg. Med. J., November 1, 2005; 22(11): 766 - 771. [Abstract] [Full Text] [PDF]

				G. Thabut and D. Logeart Thrombolysis for Pulmonary Embolism in Patients With Right Ventricular Dysfunction: Con Arch Intern Med, October 24, 2005; 165(19): 2200 - 2203. [Full Text] [PDF]

				S. Wan, D. J. Quinlan, G. Agnelli, and J. W. Eikelboom Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism: A Meta-Analysis of the Randomized Controlled Trials Circulation, August 10, 2004; 110(6): 744 - 749. [Abstract] [Full Text] [PDF]

				J. W. Kreit The Impact of Right Ventricular Dysfunction on the Prognosis and Therapy of Normotensive Patients With Pulmonary Embolism Chest, April 1, 2004; 125(4): 1539 - 1545. [Abstract] [Full Text] [PDF]

				N. Meneveau, L. P. Ming, M. F. Seronde, N. Mersin, F. Schiele, F. Caulfield, Y. Bernard, and J.-P. Bassand In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy Eur. Heart J., August 1, 2003; 24(15): 1447 - 1454. [Abstract] [Full Text] [PDF]

				C. Kearon Natural History of Venous Thromboembolism Circulation, June 17, 2003; 107(90231): I-22 - 30. [Abstract] [Full Text] [PDF]

				N. Kucher, C.M. Luder, T. Dornhofer, S. Windecker, B. Meier, and O.M. Hess Novel management strategy for patients with suspected pulmonary embolism Eur. Heart J., February 2, 2003; 24(4): 366 - 376. [Abstract] [Full Text] [PDF]

				J. E. Dalen The Uncertain Role of Thrombolytic Therapy in the Treatment of Pulmonary Embolism Arch Intern Med, December 9, 2002; 162(22): 2521 - 2523. [Full Text] [PDF]

				G. Agnelli, C. Becattini, and T. Kirschstein Thrombolysis vs Heparin in the Treatment of Pulmonary Embolism: A Clinical Outcome-Based Meta-analysis Arch Intern Med, December 9, 2002; 162(22): 2537 - 2541. [Abstract] [Full Text] [PDF]

				G. Thabut, D. Thabut, R. P. Myers, B. Bernard-Chabert, R. Marrash-Chahla, H. Mal, and M. Fournier Thrombolytic therapy of pulmonary embolism: A meta-analysis J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1660 - 1667. [Abstract] [Full Text] [PDF]

				J. E. Dalen Pulmonary Embolism: What Have We Learned Since Virchow?: Treatment and Prevention Chest, November 1, 2002; 122(5): 1801 - 1817. [Full Text] [PDF]

				S. Konstantinides, A. Geibel, G. Heusel, F. Heinrich, W. Kasper, and the Management Strategies and Prognosis of Pulmona Heparin plus Alteplase Compared with Heparin Alone in Patients with Submassive Pulmonary Embolism N. Engl. J. Med., October 10, 2002; 347(15): 1143 - 1150. [Abstract] [Full Text] [PDF]

				K. E. Wood Major Pulmonary Embolism : Review of a Pathophysiologic Approach to the Golden Hour of Hemodynamically Significant Pulmonary Embolism Chest, March 1, 2002; 121(3): 877 - 905. [Abstract] [Full Text] [PDF]

				S. Z. Goldhaber Thrombolysis in Pulmonary Embolism: A Large-Scale Clinical Trial Is Overdue Circulation, December 11, 2001; 104(24): 2876 - 2878. [Full Text] [PDF]

				E. Hamel, G. Pacouret, D. Vincentelli, J. F. Forissier, P. Peycher, J. M. Pottier, and B. Charbonnier Thrombolysis or Heparin Therapy in Massive Pulmonary Embolism With Right Ventricular Dilation : Results From a 128-Patient Monocenter Registry Chest, July 1, 2001; 120(1): 120 - 125. [Abstract] [Full Text] [PDF]

				Guidelines on diagnosis and management of acute pulmonary embolism Eur. Heart J., August 2, 2000; 21(16): 1301 - 1336. [PDF]

				G. Sharma, E. D Folland, K. M McIntyre, and A. A Sasahara Long-term benefit of thrombolytic therapy in patients with pulmonary embolism Vascular Medicine, May 1, 2000; 5(2): 91 - 95. [Abstract] [PDF]

				S. Z Goldhaber A contemporary approach to thrombolytic therapy for pulmonary embolism Vascular Medicine, May 1, 2000; 5(2): 115 - 123. [Abstract] [PDF]

				S. M. Arcasoy and J. W. Kreit Thrombolytic Therapy of Pulmonary Embolism: A Comprehensive Review of Current Evidence Chest, June 1, 1999; 115(6): 1695 - 1707. [Abstract] [Full Text] [PDF]

				C. G. Elliott Thrombolytic Therapy for Acute Pulmonaqy Embolism: Can Mortality Be Decreased? Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(1_suppl): S32 - S37. [PDF]

				R. D. Hull and G. F. Pineo Overview of Treatment of Venous Thromboembolism Based on Levels of Evidence Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(1_suppl): S68 - S71. [PDF]